Drug intelligence / Profile preview

bexsero + nimenrix + paracetamol

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules, Vaccines & Immunotherapeutics
Administration
Intramuscular, Oral
01

Overview

This is a **combination of three substances**: - **Bexsero** is a recombinant multicomponent vaccine against *Neisseria meningitidis* serogroup B. It consists of four antigenic components: factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and outer membrane vesicles (OMV) from *Neisseria meningitidis* group B. It stimulates the immune system to produce antibodies that are bactericidal against the organism, providing protection against invasive MenB disease[2][4][6]. - **Nimenrix** is a conjugate vaccine against meningococcal serogroups A, C, W, and Y. It contains polysaccharides from these serogroups, each conjugated to tetanus toxoid protein carrier, which boosts immunogenicity by inducing T-cell dependent immunity against the meningococcal bacteria[5]. - **Paracetamol** (acetaminophen) is a widely used non-opioid analgesic and antipyretic that acts centrally, largely by inhibiting prostaglandin synthesis in the brain and modulating the endogenous cannabinoid system. Used to treat pain and fever; sometimes given prophylactically in infants receiving immunization to reduce fever. This combination may be administered together (not as a premixed formulation, but as co-administration in vaccination sessions for infants/children) to provide protection against multiple types of meningococcal disease while managing fever and discomfort due to immunization.

Other names
meningococcal group B vaccine + meningococcal ACWY conjugate vaccine + acetaminophen
02

Targets

Neisseria meningitidis capsular polysaccharide

Beyond the preview

Go deeper on bexsero + nimenrix + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bexsero + nimenrix + paracetamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call